Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate of ...
William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval ...
Wells Fargo analyst Derek Archila maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and raises the price target...
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Buy and raises the pr...
KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with d...
Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for ...
Wells Fargo analyst Derek Archila maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and raises the price target...
